<DOC>
	<DOC>NCT02719158</DOC>
	<brief_summary>This is a 1-month, prospective, multicenter, randomized, dose-ranging, sham-controlled, blinded study in which eligible subjects with either unilateral or bilateral acute otitis media with tympanostomy tubes (AOMT) will receive a single administration of 6 mg OTO-201, 12 mg OTO-201, or sham into the affected ear(s).</brief_summary>
	<brief_title>Dose Ranging Study of OTO-201 in AOMT</brief_title>
	<detailed_description />
	<mesh_term>Otitis</mesh_term>
	<mesh_term>Otitis Media</mesh_term>
	<mesh_term>Ciprofloxacin</mesh_term>
	<criteria>Inclusion Criteria includes, but is not limited to: Subject is a male or female aged 6 months to 17 years, inclusive Subject has a clinical diagnosis of acute otitis media with tympanostomy tubes (AOMT) Subject's caregiver is willing to comply with the protocol an attend all study visits Exclusion Criteria includes, but is not limited to: Subject has a history of sensorineural hearing loss Subject has tympanic membrane perforation other than the surgical tympanostomy tube perforation Subject has a history of known immunodeficiency disease</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Acute otitis media with tympanostomy tubes</keyword>
	<keyword>OTIPRIO</keyword>
</DOC>